β-Blockers in COPD: A Cohort Study From the TONADO Research Program.
Autor: | Maltais F; Centre de Recherche, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec City, QC, Canada. Electronic address: Francois.Maltais@fmed.ulaval.ca., Buhl R; Pulmonary Department, Mainz University Hospital, Mainz, Germany., Koch A; Medizinische Klinik und Poliklinik V, Klinikum der Ludwig-Maximilians-Universität, and the German Center for Lung Research (DZL), Klinikum der Ludwig-Maximilians-Universität, Munich, Germany., Amatto VC; Boehringer Ingelheim International GmbH, Ingelheim, Germany., Reid J; Dunedin School of Medicine, University of Otago, Dunedin, New Zealand., Grönke L; Boehringer Ingelheim International GmbH, Ingelheim, Germany., Bothner U; Boehringer Ingelheim International GmbH, Ingelheim, Germany., Voß F; Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany., McGarvey L; Centre for Infection and Immunity, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, Northern Ireland., Ferguson GT; Pulmonary Research Institute of Southeast Michigan, Farmington Hills, MI. |
---|---|
Jazyk: | angličtina |
Zdroj: | Chest [Chest] 2018 Jun; Vol. 153 (6), pp. 1315-1325. Date of Electronic Publication: 2018 Jan 31. |
DOI: | 10.1016/j.chest.2018.01.008 |
Abstrakt: | Background: Cardiovascular disease is a frequent comorbidity in patients with COPD. Many physicians, particularly pulmonologists, are reluctant to use β-adrenoceptor blocking agents (β-blockers) in patients with COPD, despite their proven effectiveness in preventing cardiovascular events. Methods: The large (5,162 patients) phase III TONADO 1 and 2 studies assessed lung function and patient-reported outcomes in patients with moderate to very severe COPD receiving long-acting bronchodilator treatment across 1 year. This post hoc analysis characterized lung-function changes, patient-reported outcomes, and safety in the subgroup of patients receiving β-blockers in the studies. Results: In total, 557 of 5,162 patients (11%) received β-blockers at baseline. Postbronchodilator FEV Conclusions: Lung function, overall respiratory status, and safety of tiotropium/olodaterol were not influenced by baseline β-blocker treatment in patients with moderate to very severe COPD. Results from this large patient cohort support the cautious and appropriate use of β-blockers in patients with COPD and cardiovascular comorbidity. Trial Registry: ClinicalTrials.gov; No.: NCT01431274 and No. NCT01431287; URL: www.clinicaltrials.gov. (Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.) |
Databáze: | MEDLINE |
Externí odkaz: |